€2.43
Your prediction
Description Esperion
Esperion Therapeutics, Inc. (Symbol: ESPR) is a public biopharmaceutical company that is primarily focused on the development and commercialization of innovative medicine to provide better treatments for patients suffering from elevated low-density lipoprotein cholesterol (LDL-C). The company's leading product is NEXLETOL, an oral, once-daily, non-statin LDL-C lowering drug approved by the FDA in February 2020. The drug is designed for patients with hypercholesterolemia or atherosclerotic cardiovascular disease.
Headquartered in Ann Arbor, Michigan, Esperion was founded by Roger S. Newton, Ph.D., who also co-discovered the market-leading statin Lipitor. The company's goal is to provide patients with options for lower cholesterol levels and reduce the risk of cardiovascular events. They focus on the research, development, and commercialization of therapies that specifically target LDL-C, often referred to as "bad cholesterol."
Esperion's main compounds use an ATP citrate lyase (ACL) inhibitor technology to lower LDL-C by reducing cholesterol biosynthesis and up-regulating the expression of LDL-receptors on the surface of liver cells. This increased receptor expression enhances the body's natural ability to filter out circulating LDL-C from the bloodstream.
As a publicly traded company in the stock market, Esperion's stock performance can be influenced by various factors, such as the overall financial performance of the company, clinical trial results, approval of new drugs by regulatory authorities, market demand for its products, and competition from other pharmaceutical companies. Investors should consider these factors when analyzing Esperion's stock as an investment opportunity.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Esperion
sharewise wants to provide you with the best news and tools for Esperion, so we directly link to the best financial data sources.